Aktienanalyse zu argenx SE (ARGX)ARGXargenx SE

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications. It operates in the Healthcare sector.

Argenx SE (ARGX) is a good buy right now due to its strong financial performance, highlighted by a 54% year-over-year increase in Q3 sales to $1.7 billion and a gross margin of 90.41%. Despite recent setbacks in clinical trials, the company is expanding its pipeline and has a robust operating profit of $486 million. The main risk is the recent trial discontinuation, which contributed to a 14% drop in stock price, but the overall growth trajectory and analyst support suggest a favorable investment opportunity.

5 analysts cover ARGX: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 1,048.